127 related articles for article (PubMed ID: 36564983)
41. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
42. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.
Shankar RR; Xu L; Golm GT; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
Int J Clin Pract; 2015 Jun; 69(6):626-31. PubMed ID: 25652751
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
45. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Frias JP; Zimmer Z; Lam RLH; Amorin G; Ntabadde C; Iredale C; O'Neill EA; Engel SS; Kaufman KD; Makimura H; Crutchlow MF
Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
47. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
[TBL] [Abstract][Full Text] [Related]
48. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
50. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
51. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
[TBL] [Abstract][Full Text] [Related]
53. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
[TBL] [Abstract][Full Text] [Related]
54. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Scott R; Morgan J; Zimmer Z; Lam RLH; O'Neill EA; Kaufman KD; Engel SS; Raji A
Diabetes Obes Metab; 2018 Dec; 20(12):2876-2884. PubMed ID: 30019498
[TBL] [Abstract][Full Text] [Related]
55. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
56. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
[TBL] [Abstract][Full Text] [Related]
57. Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Suzuki R; Eiki JI; Moritoyo T; Furihata K; Wakana A; Ohta Y; Tokita S; Kadowaki T
Diabetes Obes Metab; 2018 Sep; 20(9):2274-2281. PubMed ID: 29770541
[TBL] [Abstract][Full Text] [Related]
58. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Yang HK; Min KW; Park SW; Chung CH; Park KS; Choi SH; Song KH; Kim DM; Lee MK; Sung YA; Baik SH; Kim IJ; Cha BS; Park JH; Ahn YB; Lee IK; Yoo SJ; Kim J; Park IeB; Park TS; Yoon KH
Endocr J; 2015; 62(5):449-62. PubMed ID: 25819061
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
60. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]